Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans

Archives of Ophthalmology

Volumn 115, Issue 1, 1997, Pages 45-49

  Maus, Todd L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 BENZOTHIAZOLESULFONAMIDE; 6 PIVALOYLOXY 2 BENZOTHIAZOLESULFONAMIDE; ACETAZOLAMIDE; APRACLONIDINE; BETAXOLOL; CARBONATE DEHYDRATASE; CLONIDINE; DORZOLAMIDE; HYDROXYPROPYLMETHYLCELLULOSE; HYPOTEARS; LEVOBUNOLOL; SEZOLAMIDE; TIMOLOL;

ADULT; AQUEOUS HUMOR FLOW; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031023338     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1997.01100150047008     Document Type: Article

References (45)

1. Roblin RO, Clapp JW. The preparation of heterocyclic sulfonamides. J Am Chem Soc. 1950;72:4890-4892.
2. Miller WH, Dessert AM, Roblin RO Jr. Hererocyclic sulfonamide as carbonic anhydrase inhibitors. J Am Chem Soc. 1950;72:4893-4896.
3. Grant WM, Trotter RR. Diamox (acetazolamide) in treatment of glaucoma. Arch Ophtha/mol. 1954;51:735-739.
4. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol. 1954;37:13-15.
5. Breinin GM, Gortz H. Carbonic anhydrase inhibitor acetazolamide (Diamox): a new approach to the therapy of glaucoma. Arch Ophthalmol. 1954;52:333-348.
6. Maren TH, Haywood JR, Chapman SK, Zimmerman TZ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol. 1977;16:730-742.
7. Wistrand PJ, Garg LCL Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Invest Ophthalmol Vis Sci. 1979;18:802-806.
8. Wistrand PJ, Schenholm M, Lonnerholm G. Carbonic anhydrase isoenzymes CA I and CA II in human eye. Invest Ophthalmol Vis Sci. 1986;27:419-428.
9. Maren TH, Jankowska L, Sanyal G, Edelhauser HF. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res. 1983;36:457-480.
10. Stein A, Pinke R, Krupin T, et al. The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits. Am J Ophthalmol. 1983;95:222-228.
11. Lewis RA, Schoenwald RD, Eller MG, Barfknecht CF, Phelps CD. Ethoxzolamide analogue gel. Arch Ophthalmol. 1984;102:1821-1824.
12. Schoenwald RD, Eller MG, Dixson JA, Barfknecht CF. Topical carbonic anhydrase inhibitors. J Med Chem. 1984;27:810-812.
13. Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF. 6-Amino-2-benzothiazolesulfonamide: the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmology. 1988;95:772-777.
14. Sugrue MF, Mallorga P, Schwam H, Baldwin JJ, Ponticello GS. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res. 1990;9:607-615.
15. Sugrue MF, Gautheron P, Schmitt C, et al. On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor. J Pharmacol Exp Ther. 1985;232:534-540.
16. Ponticello GS, Freedman MB, Habecker CN, et al. Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors. J Med Chem. 1987;30:591-597.
17. Bron AM, Lippa EA, Hofmann HM, etal. MK-927: a topically effective carbonic anhydrase inhibitor in patients. Arch Ophthalmol. 1989;107:1143-1146.
18. Pfeiffer N, Hennekes R, Lippa EA, Grehn F, Garus H, Brunner-Ferber FL A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Er J Ophthalmol. 1990;74:405-408.
19. Matuszewski BK, Constanzer ML. Indirect chiral separation and analyses in human biological fluids of the stereoisomers of a thienothiopyran-2-sulfonamide (Trusopt), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule. Chirality. 1992;4:515-519.
20. Kitazawa Y, Azuma I, Iwata K, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma. 1994;3:275-279.
21. Lippa EA, Carlson L-E, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495-499.
22. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 1991;98:308-313.
23. Gunning FP, Greve EL, Bron AM, et al. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefes Arch Clin Exp Ophthalmol. 1993;231:384-388.
24. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111:1343-1350.
25. Yamazaki Y, Miyamoto S, Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1994;38:92-96.
26. The MK-507 Clinical Study Group. Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J Glaucoma. 1995;4:6-10.
27. Strahlman E, Tipping R, Vogel R, the International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol. 1995;113:1009-1016.
28. Wang R-F, Serie JB, Podos SM, Sugrue MF. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-1299.
29. Johnson S, Coakes RL, Brubaker RF. A simple photogrammetric method of measuring anterior chamber volume. Am J Ophthalmol. 1978;85:469-474.
30. Brubaker RF. Clinical evaluation of the circulation of aqueous humor. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology. Philadelphia, Pa: JB Lippincott; 1990;3(chap 46):1-11.
31. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32:3145-3166.
32. Dixon WJ, Massey JF Jr. Introduction to Statistical Analysis. New York, NY: McGraw-Hill Book Co; 1969:516.
33. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232-237.
34. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315-1319.
35. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol. 1992;230:518-520.
36. Gharagozloo NZ, Reif SJ, Brubaker RF. Aqueous flow is reduced by the alphaadrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988;95:1217-1220.
37. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology. 1983;90:1369-1372.
38. Lee DA, Topper JE, Brubaker RF. Effect of clonidine on aqueous humor flow in normal human eyes. Exp Eye Res. 1984;38:239-246.
39. Gaul GR, Will NJ, Brubaker RF. Comparison of a noncardioselective β-adrenoceptor blocker and a cardioselective blocker in reducing aqueous flow in humans. Arch Ophthalmol. 1989;107:1308-1311.
40. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135-142.
41. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure: in the normal eye. Arch Ophthalmol. 1978;96:2045-2048.
42. Larsson L-l, Rettig ES, Brubaker RF. Aqueous flow in open-angle glaucoma. Arch Ophthalmol. 1995;113:283-286.
43. Larsson L-l, Rettig ES, Sheridan PT, Brubaker RF. Aqueous humor dynamics in low-tension glaucoma. Am J Ophthalmol. 1993;116:590-593.
44. Gharagozloo NZ, Baker RH, Brubaker RF. Aqueous dynamics in exfoliation syndrome. Am J Ophthalmol. 1992;114:473-478.
45. Brown JD, Brubaker RF. A study of the relation between intraocular pressure and aqueous humor flow in the pigment dispersion syndrome. Ophthalmology. 1989;96:1468-1470.